

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



54


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61M 5/30, A61J 1/00, F17C 13/06		A1	(11) International Publication Number: WO 99/01168 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/GB98/01963 (22) International Filing Date: 3 July 1998 (03.07.98) (30) Priority Data: 97304908.3 4 July 1997 (04.07.97) EP (71) Applicant (for all designated States except US): POWDER-JECT RESEARCH LIMITED [GB/GB]; 4 Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): POTTER, Charles, David, Ogilvy [GB/GB]; Denham House, Church End, Stardlake OX8 7SG (GB). POTTER, David, S. [GB/GB]; 2 Cliff Road, Cowes, Isle of Wight PO31 8BN (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).			(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.

(54) Title: DRUG PARTICLE DELIVERY

(57) Abstract

A needleless drug particle delivery device, of the kind in which firing of the drug particles is caused by a sudden gas flow, characterised in that the device comprises a container (14) of compressed gas and a mechanism for releasing the gas from the container to create the gas flow, the mechanism comprising a rupture (20) element for breaching the container and a manually manipulable actuator (27) for moving the element and the container relatively to one another to provide an initial breach whereby gas is released to act on a piston portion (21) to provide a servo action which causes the rupture element and container to move further suddenly relatively to one another to complete the breaching of the container and establish a maximum gas flow from the container.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DRUG PARTICLE DELIVERY

In our earlier international patent applications Nos. WO 94/24263, WO 96/04947, WO 96/12513, WO 96/20022 and
5 WO 96/25190, we disclosed various non-invasive drug delivery systems involving the use of a delivery device such as a needleless syringe or catheter which fires particles consisting of or containing a drug (which term includes genetic material) in controlled doses into body
10 tissue, e.g. through the intact skin, for curative, prophylactic, diagnostic or other medical treatment.

The devices described in the earlier applications are constructed as a tubular nozzle or other lumen, a rupturable element initially closing the passage through
15 the lumen adjacent to the upstream end of the lumen, drug particles located adjacent to the lumen, and energising means for applying to the upstream side of the element a gaseous pressure sufficient to burst the element and to produce within the lumen a supersonic condition and hence
20 cause the particles to be fired from the downstream end of the lumen. In a first type of syringe, the supersonic condition is a supersonic flow of the gas through a nozzle, in which the drug particles are entrained. In that case the particles may be initially located within a rupturable
25 capsule which provides the rupturable element. In the second type of syringe or catheter, the downstream end of the lumen is provided with a bistable diaphragm, which is movable between an inverted position in which it presents outwardly of the lumen a concavity containing the
30 particles, and an everted, outwardly convex, position. The supersonic condition is then a supersonic shockwave which is arranged to snap the diaphragm over from its inverted to its everted position, and to catapult the particles outwardly.

35 The energising means disclosed in the earlier applications has, in general, involved the use of a container for compressed gas, the container having an

outlet provided with a valve which is opened manually by the operator. Various kinds of valves have been proposed, including a ball valve, in which the ball is pushed off its seat, a piston which is pushed out of sealing engagement with a cylindrical passageway, and a hollow needle which is advanced to pierce a foil closing the container outlet. However, all these solutions suffer from the possible disadvantage that upon manual operation to open the valve, the immediate and subsequent gas flow will depend upon the manipulation of the valve by the operator. In particular, if the valve is not fully opened quickly, the gas may not escape at the desirable maximum flow rate. In contrast, it is desirable that the escape of gas from the container should be substantially immediate, unimpeded, and reliably reproducible on every occasion, so that the characteristics of delivery of the dose of particles, and hence the depth of penetration into the patient, are accurately predetermined.

In accordance with the present invention, a needleless drug particle delivery device, of the kind in which firing of the drug particles is caused by a sudden gas flow, is characterised in that the device comprises a container of compressed gas and a mechanism for releasing the gas from the container to create the gas flow, the mechanism comprising a rupture element for breaching the container and a manually manipulable actuator for moving the element and the container relatively to one another to provide an initial breach whereby gas is released to act on a piston portion to provide a servo action which causes the rupture element and container to move further suddenly relatively to one another to complete the breaching of the container and establish a maximum gas flow from the container.

With this construction, after the container has been breached manually, and the gas has been released into a volume, which will normally remain fixed while the gas pressure builds up to a value at which resistance to movement of the piston portion is overcome, the servo

action will take over and cause full release of the gas in a predetermined manner, irrespective of any uncertain manipulation of the actuator.

5 The gas flow may be arranged to burst and then flow through a rupturable membrane to cause a shockwave to be transmitted along a lumen to an evertible diaphragm. Alternatively the gas flow may open a drug particle-containing capsule, by bursting a rupturable wall of the capsule or otherwise, to enable the gas flow to entrain
10 particles contained in the capsule.

The rupture element may be a pusher for initially cracking, and subsequently substantially snapping off, a tip of the compressed gas container. Alternatively, the rupture element may be a piercing device, such as a hollow
15 needle, for piercing a foil closing an outlet of the container, or a cutter or blade to cut or slice the outlet of the container.

The actuator may be a slidable or rotary finger or thumb piece provided with a ramp or other cam for providing
20 the initial displacement of the rupture element upon movement of the actuator relatively to a body of the device. When the actuator moves linearly relatively to the rupture element, it may be moved by shortening the device telescopically, eg by pushing a part at the upstream end of
25 the device with a part at the downstream end of the device in contact with the target until the container is breached. In either case the outlet of the container may point towards the upstream end of the device to minimise the possibility of any fragments, which are produced upon
30 rupture of the container, being entrained by the gas and adulterating the particles. Equally, the container outlet may point downstream.

Although the piston portion could be formed on the gas container or by part of a cradle for the gas container, it
35 is most simply provided for movement with, and normally integrated with, the rupture element. In one compact arrangement, the drug particles are arranged to be

contained within a capsule, particularly a capsule with rupturable walls, which is mounted within a hollow piston, itself integrated with the rupture element. With this arrangement the rupture element and piston are moved a small distance by manual manipulation of the actuator to breach the container whereafter the gas pressure advances the piston and completes the breaching of the container, until the piston bottoms out. The full gas pressure is then applied to the capsule which is thus opened by rupture of its wall or otherwise, to release the full gas flow through the piston and capsule with the particles entrained in the flow.

In one arrangement of this invention the gas container is a cartridge fitted with a protruding nib-end that can be broken off to reveal an aperture through which the gas can escape. A primary manual leverage action has only to bend over the nib-end a short distance out-of-line in order to initiate a fracture crack and release gas at its junction with the cartridge. The consequent intensification of gas pressure behind the servo-piston propels the nib-end a farther distance out-of-line, progressively enlarging the aperture and, with an increased flowrate of gas, accelerating the movement until the nib-end shears off nearly or completely. This secondary servo action takes place automatically without any additional manual effort or travel, and the nib-end is held captive by the servo-piston element to prevent its interfering with or becoming entrained in the gas stream from the cartridge. This two-stage system of breaching the gas cartridge benefits from the rapidly increasing pressure force applied to the servo-piston, whereas other possible breaching mechanisms may have a constant level or suffer from a diminution of energy after making their initial impact movement.

The depth of dermal penetration of the drug particles is dependent upon the velocity at which the particles are delivered, and this in turn depends upon the velocity of the gas flow in which the particles are entrained, or the

velocity of the shockwave when the particles are ejected from an evertible diaphragm. Different drugs need to be delivered to different depths in the tissue at which their activity is maximised. Skin of persons of different age has different penetrability. It is therefore desirable to be able to control accurately, and with reliable reproducibility, the velocity at which the drug particles are delivered, and for the velocity to be adjustable so that a single syringe can be used with different drugs and with persons of different age. We have appreciated that a simple way of being able to adjust the particle velocity is to set the maximum flow of gas from the container. This in turn can be achieved by adjusting the extent to which the container is breached, when the breaching has been completed, thereby utilising an adjustable restriction to the outflow of gas from the container. A simple way of providing such adjustment in the maximum gas flow is to provide an adjustable stop which limits the stroke of the piston portion at a set position. For example, when the container is a cartridge fitted with a protruding nib-end, progressive bending of the nib-end out-of-line, will progressively open the cartridge outlet and hence progressively increase the gas flow. Limiting the stroke of the piston portion, by appropriate setting of the stop, will then provide a predetermined gas flow from the cartridge.

Some examples of needleless syringes constructed in accordance with the present invention are illustrated diagrammatically in the accompanying drawings, in which:

Figs. 1 to 4 and 6 are central sections through five different syringes;

Fig. 5 is a section taken on the line V-V in Fig. 4; and,

Fig. 7 is a section, corresponding to Fig. 1 but showing a modification.

The syringe of Fig.1 has a barrel 10, having, near its upper end, an annular wing 11. The barrel is provided on

its inner wall with a plurality of circumferentially spaced axial ribs 12 defining between adjacent ones of the ribs a plurality of channels. Near its lower end the barrel is provided with a number of radially extending castellations 13. The barrel thus provides a housing for a sealed cartridge 14 of compressed helium at a pressure of, typically, between 40 and 80 bar. The cartridge has a frangible tip 15. When preparing the syringe for use the cartridge is inserted into the barrel 10 until it comes to rest on castellations 13, and is then secured in place by the bottom of a downwardly extending skirt 16 on an upper housing part 17 which is screwed into an upper end portion 19 of the barrel 10. The inner wall of the skirt 16 is also provided with a plurality of circumferentially spaced axial ribs 18 defining between adjacent ones of the ribs a plurality of channels which communicate at their lower ends via an annular groove 18A with the upper ends of the channels between the ribs 12.

The housing 17 contains a rupture element 20 having an annular piston portion 21, which slides within a cylindrical portion 22 of the housing, and a leg 23 which is slidable within a through hole in an end wall 25 of the housing. The leg 23 has a gate 26 through which the tip 15 of the cartridge projects. Slidable over and around the housing 17 is an actuator cap 27 having a chamfered cam surface 28 initially in light engagement with the tip of the leg 23.

The lower part of the syringe is very similar to that illustrated in Fig. 1 of WO 94/24263. Thus the internally screw threaded lower end of the barrel 10 is screwed over the outside of a nozzle 29 containing a passageway with a short upstream convergent section 30 and a downstream longer divergent section 31. Sandwiched between a shoulder 32 on the barrel 10 and the upper end of the nozzle 29 is a drug capsule 33. This is constructed like the capsule illustrated in Fig. 8 of WO 94/24263 and comprises an annular ring, having a frusto conical internal periphery

surrounding a compartment containing the drug particles to be injected. The top and bottom of the compartment are closed by rupturable Mylar diaphragms which are bonded and sealed to the upper and lower walls of the ring so that the capsule forms a self contained sealed unit. The capsule is sealed to the shoulder 32 and nozzle 29 by interposed O rings recessed into the capsule ring and nozzle respectively. The frusto conical internal periphery of the capsule ring forms a continuation of the frusto conical upstream section of the passage through the nozzle 29.

The nozzle 29 is surrounded, downstream of its screw threaded connection to the barrel 10, by a tubular portion providing a divergent spacer shroud 34 and a cylindrical silencer part 35, made and assembled as described in WO 94/24263. The inner surface of the cylindrical part 35 is integrally formed with a number of axially spaced, radially inwardly projecting baffles 36. The outer surface of the nozzle is complementarily provided with a series of radially outwardly extending baffles 37, each axially spaced equidistant between a respective adjacent pair of the baffles 35. A ring of exhaust vents 38 is formed in the cylindrical part 35, adjacent to its upper end.

In use the syringe is prepared, if not supplied ready prepared, by unscrewing the barrel 10 from the nozzle 29, inserting a capsule 33 and screwing the barrel and nozzle together again. The housing 17 is unscrewed from the barrel 10 and a helium cartridge 14 inserted, prior to screwing the housing and barrel together again.

To operate the syringe, the downstream wider end of the spacer shroud 34 is pressed against the patient's skin and, for example, with the cap in the palm of the operator's hand, and his first and second fingers engaging beneath the wing 11, the cap is pressed down over the housing 17 so that the chamfered cam surface 28 forces the rupture element 20 to move slightly to the right as seen in Fig. 1. This begins to bend and break off the tip 15 of the cartridge 14, as a result, perhaps, of a preformed nick

or other point of weakness in the tip, which may be made of an aluminium alloy, and hence breaches the integrity of the cartridge. This releases some gas from the cartridge and the gas builds up pressure behind the annular surface of the piston head 21 around the leg 23. The gas pressure then provides a servo action which suddenly forces the rupture element 20 to the right as seen in Fig. 1, thereby snapping fully open the frangible end of the cartridge tip 15. The compressed helium in the cartridge is then free to flow quickly through the channels in the wall of the skirt 16 and in the wall of the barrel 10 around the cartridge 14, into a rupture chamber 39 formed within the barrel upstream of the capsule 33. When the pressure has built up sufficiently in this rupture chamber, the diaphragms of the capsule 33 are ruptured and a supersonic flow of gas through the nozzle 29, in which the drug particles from within the capsule 33 are entrained, is released. These particles impinge upon, and penetrate, the patient's skin, to the required depth. The shockwave reflected from the patient's skin is transmitted back through the tortuous passage in the silencer between the interdigitating baffles 36 and 37, and is eventually vented to atmosphere through the vents 38. Depending upon the circumstances, the syringe, is then disposed of or recharged with a new drug capsule and gas cartridge.

The syringe shown in Fig. 2 is similar in construction and function to that of Fig. 1 and corresponding parts are given the same reference numerals with the suffix A. The essential differences are as follows. The housing 17A, containing the rupture element 20A is screwed to the barrel 10A and is fixed relatively to the actuator cap 27A. The left hand side of the barrel 10A as seen in Fig. 2, has an enlarged thickness containing a longitudinal bore in which there slides an actuator spear 40 having a chamfered tip 41 which initially loosely engages the leg of the rupture element 20A. The lower end of the spear 40 abuts against the upper end of a cylindrical shroud 35A which is slidably

mounted in the bottom of the barrel 10A. The downstream end of the shroud 35 provides a spacer 34A extending beyond the downstream end of the nozzle 29A but is not flared as, in this case, this is unnecessary owing to the larger
5 divergence of the downstream section of the passage through the nozzle 29A, which allows sufficient spread of the drug particles. However, the cylindrical portion 35A is provided with baffles 36A, interdigitating with baffles 37A to provide a silencer.

10 In operation the downstream end of the spacer portion 34A is pressed against the patient's skin and axial pressure is applied to the cap 27A. This causes the parts other than the shroud and spear element 40 to move towards the target, hence causing the chamfered tip 41 of the spear
15 40 to force the rupture element 20A to the right as seen in Fig. 2 and crack open the tip of the cartridge 14A. Thereafter the operation is as described with reference to Fig. 1. It will be appreciated that as the nozzle 29A moves downwards relatively to the shroud 35A, the baffles
20 36A and 37A move to positions in which each is substantially equidistant between a pair of the others to maximise the silencing effect.

In the example shown in Fig. 3, parts analogous in function to those in Fig. 1 are given the same reference
25 numeral with the suffix B.

In this example the barrel is in two parts 10B which are held together by a screw 43, with the helium cartridge 14B sandwiched between them. A line of weakness 44 in the tip 26B can be seen. The upper part 10B of the barrel, as
30 seen in Fig. 3, is formed integrally with a housing 17B containing a slidable rupture element 20B. The nozzle 29B is connected by a screw thread to the upper barrel portion 10B and provides, in conjunction with the housing 17B, a cylinder 45 in which the piston end 21B of the element 20B
35 slides. The end of the rupture element beyond the piston 21B carries a drug particle capsule in the form of a blister pack 46 having a peripheral flange which is secured

in a countersunk recess in the element 20B by a cylindrical retaining element 47 which is a force fit into the recess.

The nozzle 29B has a cylindrical shroud which provides both a spacer portion 34B, and a silencer portion 35B surrounding the downstream end of the nozzle 29B with a clearance, which may provide a tortuous path through which a shockwave may be vented to atmosphere through vents 38B. In this case an actuator is formed by a thumb piece of angular shape which is pivoted at one end between clevis flanges 48 projecting integrally from the upper barrel portion 10B.

The syringe is operated by grasping the barrel and applying anti-clockwise pressure, as seen in Fig. 3, to the actuator 47. This displaces the rupture element 20B slightly to the left, cracking the tip 26B of the cartridge 14B and releasing a precursor gas flow into the space behind the piston 21B. The piston is thus forced sharply to the left, as seen in Fig. 3, fully opening the cartridge under the servo action of the gas, until the element bottoms out against the shoulder 49 in the nozzle 29B. Further build up of gas behind the capsule 46 eventually causes the walls of the blister pack to rupture and to release through the nozzle 29B a supersonic gas flow in which the drug particles are entrained, to impinge and penetrate the patient's skin against which the open end of the spacer portion 34B of the shroud is pressed.

The Figs. 4 and 5 example shows another gas release mechanism in accordance with the invention but for generating a shock wave to evert a drug particle-containing diaphragm, as described in WO 96/20022, instead of for generating a supersonic gas flow in which drug particles are entrained, as disclosed in WO 94/24263. Indeed, the Fig. 4 example differs only from the Figs. 1 to 3 example of WO 96/20022 in the gas release mechanism.

Thus the Fig. 4 syringe has an upper tubular portion 50, having a separate perforated internal support 51 on which there rests a cartridge 52 of compressed helium. A

housing 53, is screwed to the tubular portion 50. An actuator cap 54, slides over the housing and is provided with a downwardly projecting rupture element 55, having, at its lower end, a sharp pointed head arranged to breach a foil seal on the upper end of the cartridge 52. The rupture element 55 slides through a central hole in a piston element 56, which can slide down around the cylindrical outer surface of an upward extension 50A of the portion 50, the piston having a central aperture smaller than the head of the element 55. The extension 50A is formed with a ring of axial passages 50B and an internal profile which forms a collar around and complements the neck of the cartridge 52 to hold the cartridge down on the support 51.

The tubular portion 50 is screw threaded to a central tubular portion 57 which in turn is screw threaded to a lower tubular portion 58. Sandwiched between a shoulder of the upper tubular portion 50 and an insert 59 in the central tubular portion 57, is a peripheral ring of a rupturable diaphragm 60 and a flange 51A of the support 51. The downstream end of the lower tubular portion 58 has screwed onto it a gland nut 61 and sandwiched between the lower end of the portion 58 and an inwardly projecting shoulder of the nut 61 is a peripheral flange of an evertible diaphragm 62 which initially presents downstream a concave configuration containing drug particles. The construction of this diaphragm and the manner in which the drug particles are retained is more fully described in WO 96/20022.

In operation of the Fig. 4 syringe, the barrel formed by the parts 50, 57, 58 is grasped in the hand and with the downstream end of the device pressed against the patient's skin, the actuator cap 54 is depressed by the operator's thumb. As a result the tip of the rupture element 55 breaches the foil closing the outlet of the cartridge 52, whereupon gas can escape up through the discontinuous central portion of the piston 56 and thereupon act upon the

upper surface of the piston. This provides a servo action causing the piston to move sharply downwardly, carrying the enlarged tip of the element 55 further into the cartridge to open the cartridge fully and allow the escape of gas
5 down through the passages 50B around the cartridge 52, and through the support 51 into a rupture chamber 63. Here the gas pressure quickly builds up until the diaphragm 60 ruptures releasing a supersonic gaseous shockwave along the shock tube 64 formed by the passage through the parts 57
10 and 58, thus causing the diaphragm 62 suddenly to evert to a convex position and catapult the drug particles into the patient's skin.

Fig. 7 shows a modification of Fig. 1, in which an adjustable stop 65 is screwed into a threaded portion of
15 the cylinder 22. The stop 65 has a projected abutment 67 against which the end of the piston portion 21 will come to rest when the gas release mechanism is operated, thereby limiting the extent to which the frangible tip 15 is bent sideways. The position of the stop 65 can be adjusted by
20 pulling off the cap 27, which is a push fit, and rotating the stop 65 by applying a screwdriver to a slot 68 in the stop, prior to refitting the cap 27.

Of course it would be possible to combine the gas release mechanism of any one of Figs. 1 to 3 or 7 with the
25 rupturable diaphragm, shock tube and evertible diaphragm of Fig. 4, as shown in Fig. 6, which shows a hybrid of Figs. 1 and 4. Equally a gas release mechanism, similar to that of the Fig. 4 example could be used to promote the particle-entraining gas flow of the Figs. 1 to 3 or 7
30 examples.

The new gas release mechanism may be used, not only in a syringe, but also other circumstances in which firing of particles by a sudden gas flow is needed, for example in a catheter as described in WO 96/20022.


CLAIMS

1. A needleless drug particle delivery device, of the kind in which firing of the drug particles is caused by a sudden gas flow, characterised in that the device comprises a container (14) of compressed gas and a mechanism for releasing the gas from the container to create the gas flow, the mechanism comprising a rupture element (20) for breaching the container and a manually manipulable actuator (27) for moving the element and the container relatively to one another to provide an initial breach whereby gas is released to act on a piston portion (21) to provide a servo action which causes the rupture element and container to move further suddenly relatively to one another to complete the breaching of the container and establish a maximum gas flow from the container.
2. A device according to claim 1, in which there is a rupturable membrane (60) which is arranged to be burst by the gas to cause a shockwave to be transmitted along a lumen (64) to an evertible diaphragm (62).
3. A device according to claim 1, wherein there is a drug particle-containing capsule (33) which is arranged to be opened by the gas flow to enable the gas flow to entrain particles contained in the capsule.
4. A device according to any one of the preceding claims, in which the rupture element is a pusher (20) for initially cracking, and subsequently substantially snapping off, a tip (15) of the compressed gas container.
5. A device according to any one of the preceding claims, in which the actuator is a slidable or rotary finger or thumb piece (27) provided with a cam (28) for providing the initial displacement of the rupture element upon movement of the actuator relatively to a body of the device.

6. A device according to any one of the preceding claims, in which the piston portion (21) is integrated with the rupture element (20).
- 5 7. A device according to any one of the preceding claims, in which the stroke of the piston portion (21) is limited by an adjustable stop (65) whereby the maximum gas flow from the container is adjustable.

1/5

Fig.1.



2/5

Fig.2.




Fig.3.




Fig.7.




Fig.4.






Fig.5.

5/5

Fig.6.



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01963

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61M5/30 A61J1/00 F17C13/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61M A61J F17C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 757 202 A (BOC GROUP PLC) 5 February 1997 see column 3, line 13 - column 4, line 36; figure 6	1
A	US 5 009 637 A (NEWMAN JACK ET AL) 23 April 1991 see column 2, line 45-68 see column 3, line 33 - column 4, line 5 see figure 1	1,3-5
A	US 4 913 699 A (PARSONS JAMES S) 3 April 1990 see column 4, line 23 - column 6, line 2 see figures 1-4	1,4,5
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 October 1998

Date of mailing of the international search report

15/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bichlmayer, K-P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01963

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 20022 A (OXFORD BIOSCIENCES LTD ;BELLHOUSE BRIAN JOHN (GB); BELL JOHN (GB)) 4 July 1996 cited in the application see figures 1,3 ---	2
A	WO 94 24263 A (OXFORD BIOSCIENCES LTD ;BELLHOUSE BRIAN JOHN (GB); BELL JOHN (GB)) 27 October 1994 cited in the application see figures 1,4,8 -----	2,3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/01963

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0757202 A	05-02-1997	AU 6076496 A	06-02-1997
		CA 2182551 A	03-02-1997
		CZ 9602264 A	12-02-1997
		HU 9602112 A	28-04-1997
		JP 9104458 A	22-04-1997
		PL 315489 A	03-02-1997
		SK 101896 A	08-04-1998
US 5009637 A	23-04-1991	AU 628029 B	10-09-1992
		AU 2563988 A	18-05-1989
		CA 1310870 A	01-12-1992
US 4913699 A	03-04-1990	AU 654420 B	03-11-1994
		AU 3035692 A	11-02-1993
		AU 628815 B	24-09-1992
		AU 3440889 A	05-10-1989
		CA 1333553 A	20-12-1994
		DE 68915162 D	09-06-1994
		DE 68915162 T	18-08-1994
		EP 0404818 A	02-01-1991
		JP 2728141 B	18-03-1998
		JP 3503374 T	01-08-1991
		KR 9709717 B	17-06-1997
		WO 8908469 A	21-09-1989
WO 9620022 A	04-07-1996	AU 4271496 A	19-07-1996
		BG 101600 A	27-02-1998
		CA 2208590 A	04-07-1996
		CN 1171055 A	21-01-1998
		CZ 9701937 A	12-11-1997
		EP 0799064 A	08-10-1997
		FI 972554 A	16-06-1997
		HU 77064 A	02-03-1998
		NO 972897 A	20-06-1997
		PL 320919 A	10-11-1997
		SK 81797 A	04-03-1998
WO 9424263 A	27-10-1994	AT 148497 T	15-02-1997
		AU 674742 B	09-01-1997
		AU 6435194 A	08-11-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/GB 98/01963

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9424263 A		BG 100047 A	30-04-1996
		BR 9406455 A	02-01-1996
		CA 2159452 A	27-10-1994
		CN 1120852 A	17-04-1996
		CZ 9502608 A	15-05-1996
		DE 69401651 D	13-03-1997
		DE 69401651 T	15-05-1997
		DK 693119 T	28-07-1997
		EP 0693119 A	24-01-1996
		EP 0734737 A	02-10-1996
		ES 2098131 T	16-04-1997
		FI 954788 A	06-10-1995
		GR 3022939 T	30-06-1997
		HU 73516 A	28-08-1996
		JP 8509604 T	15-10-1996
		LV 11833 A	20-08-1997
		LV 11833 B	20-12-1997
		NO 953994 A	06-10-1995
		NZ 263606 A	22-08-1997
		PL 311005 A	22-01-1996
		SG 48696 A	18-05-1998
		SI 693119 T	31-10-1997
		SK 124895 A	08-01-1997
		US 5630796 A	20-05-1997
		ZA 9402442 A	10-04-1995